{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/incontinence-urinary-in-women/prescribing-information/duloxetine/","result":{"pageContext":{"chapter":{"id":"2bf52d86-2720-51b1-9411-89ebb7ff9b07","slug":"duloxetine","fullItemName":"Duloxetine","depth":2,"htmlHeader":"<!-- begin field 5e937b89-7f85-43af-936c-76e6c95e02cf --><h2>Duloxetine</h2><!-- end field 5e937b89-7f85-43af-936c-76e6c95e02cf -->","summary":"","htmlStringContent":"<!-- begin item 6fca4b13-20ad-4433-a549-0ac9411b220e --><!-- end item 6fca4b13-20ad-4433-a549-0ac9411b220e -->","topic":{"id":"c16535c5-1fa2-5d4a-a89f-9863872fca0e","topicId":"9e411d60-4060-4d95-8511-0998688cea47","topicName":"Incontinence - urinary, in women","slug":"incontinence-urinary-in-women","lastRevised":"Last revised in October 2019","chapters":[{"id":"592d340e-2c89-5e8e-9781-8398ef51af2c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"93b3be44-57e0-59a2-b936-4b447f0b2961","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c15069c4-b8dd-5092-9861-e20a636b9367","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3dc5fefe-1cf0-54d7-92d3-e1c0c60c6fb9","slug":"changes","fullItemName":"Changes"},{"id":"fb9741e6-b4f0-5ec2-ada2-a14af327feed","slug":"update","fullItemName":"Update"}]},{"id":"1ae974b5-487a-5fdf-88b5-6d9ed1e83525","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"399a4681-e92c-5e84-a738-fded957e135f","slug":"goals","fullItemName":"Goals"},{"id":"6507910a-37cb-51a9-8d3d-b69725293a87","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9cd9dcb7-4d7b-5d3b-aa75-6fb40bf5928b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f79e3765-8adb-5e3f-b68f-48aa4ddeb34b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e1ab1bca-96c7-5187-894e-1e1fe32f92d6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"97c63b91-f53e-5694-b807-0899dd34d53a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0c2e43fc-1afb-59f4-8819-0ff5edc09eeb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3ab1ad04-1d9d-52bc-b4c9-ad0787598df3","slug":"definition","fullItemName":"Definition"},{"id":"a9c53f9f-2962-5eb2-8cae-91fc90a5a1f4","slug":"causes-contributing-factors","fullItemName":"Causes and contributing factors"},{"id":"4bbda54d-1a4f-591c-8463-082fcdf61d7c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e79a0901-9992-5f45-8cf5-c15ce06b5deb","slug":"complications","fullItemName":"Complications"},{"id":"b70db9b0-ddc3-5b42-888e-7171189f4ee5","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a84e9562-3c9c-5c5e-8832-06e65a89aa2f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"49f48003-2f49-51d5-acfe-7ba0fcff8fae","slug":"assessment-overview","fullItemName":"Assessment overview"},{"id":"060afa31-1619-5a1a-a7e5-bcb583129aca","slug":"assessing-the-type-of-urinary-incontinence","fullItemName":"Assessing the type of urinary incontinence"},{"id":"9897aa86-8c09-5550-8496-da8cb12787bf","slug":"assessing-for-underlying-causes-contributing-factors","fullItemName":"Assessing for underlying causes and contributing factors"},{"id":"49079af0-34b2-5cab-9135-40f57ee1eea4","slug":"assessing-for-complications","fullItemName":"Assessing for complications"},{"id":"c9c5f464-0433-5027-a22c-8d2b8fb239bd","slug":"assessing-the-severity-of-urinary-incontinence","fullItemName":"Assessing the severity of urinary incontinence"}]},{"id":"a7454b90-f574-597a-b3ce-8f0b3967e058","fullItemName":"Management","slug":"management","subChapters":[{"id":"26043de5-bad9-57d7-abad-98942e3ed62c","slug":"managing-stress-incontinence","fullItemName":"Scenario: Managing stress incontinence"},{"id":"280a972f-ec97-53b4-ab56-b67df1df40d3","slug":"managing-urgency-incontinence","fullItemName":"Scenario: Managing urgency incontinence"},{"id":"dff61990-c7a9-5600-b15a-e9098f480b65","slug":"managing-mixed-urinary-incontinence","fullItemName":"Scenario: Managing mixed urinary incontinence"},{"id":"4e21298e-b75d-5104-9b4b-a9817cb8d9b6","slug":"managing-overflow-urinary-incontinence","fullItemName":"Scenario: Managing overflow urinary incontinence"},{"id":"d5ace44e-cc5a-5618-bb48-24058af84ec8","slug":"managing-a-urogenital-fistula","fullItemName":"Scenario: Managing a urogenital fistula"}]},{"id":"d814319d-0309-591f-aa84-5dfa4933d33b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3d2d4594-7f5e-5ad4-9537-22965cd3859f","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"c57e795e-2c4a-5f04-83ae-289890ef29ea","slug":"desmopressin","fullItemName":"Desmopressin"},{"id":"2bf52d86-2720-51b1-9411-89ebb7ff9b07","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"7f2a8cea-ac55-5ac4-a58a-52dbe5d19228","slug":"intravaginal-oestrogen","fullItemName":"Intravaginal oestrogen"},{"id":"2e7111be-d25f-52ec-9f6b-2aaea7583699","slug":"mirabegron","fullItemName":"Mirabegron"}]},{"id":"3ef95f2d-4da4-5002-9243-64779078fc11","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bdb709b8-1321-594d-b446-51244a4b8f41","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ce87fd7-7343-5da1-b9a5-0035a5703c2c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3fe3b863-a1f0-5938-9f0d-bb718d670d28","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"947b96f3-7dc6-5136-96f6-431519b4646a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"16662eed-08e1-5333-85c0-65d2e4722f09","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9c5908f0-10fa-5d1c-8762-8a682a1ee2c8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"532bc548-9f39-5742-9a38-cb92893a8407","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d814319d-0309-591f-aa84-5dfa4933d33b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"245c05ae-eaad-5961-ae56-d2b2f8e3e3d7","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 0abd4ea6-20e7-41d6-8f47-d60b8656ba25 --><h3>What are the cautions and contraindications for duloxetine?</h3><!-- end field 0abd4ea6-20e7-41d6-8f47-d60b8656ba25 -->","summary":"","htmlStringContent":"<!-- begin item d6d49276-7ff3-41cb-9ce2-019cffe0afe6 --><!-- begin field 95df296d-5d91-48a2-9041-87cd6ce6f63f --><ul><li><strong>Do not prescribe duloxetine to people aged under 18 years, or people with:</strong><ul><li>Hepatic impairment.</li><li>Severe renal impairment (creatinine clearance less than 30 mL/min).</li><li>Uncontrolled hypertension.</li></ul></li><li><strong>Prescribe duloxetine with caution to people with:</strong><ul><li>A history of bleeding disorders.</li><li>A history of seizures.</li><li>A history of mania or bipolar disorder.</li><li>Cardiac disease.</li><li>Hypertension.</li><li>Susceptibility to angle-closure glaucoma, or raised intraocular pressure.</li><li>Susceptibility to hyponatraemia.</li></ul></li><li>Also prescribe with caution in elderly people.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 95df296d-5d91-48a2-9041-87cd6ce6f63f --><!-- end item d6d49276-7ff3-41cb-9ce2-019cffe0afe6 -->","subChapters":[]},{"id":"c0b56066-f42f-5b49-97df-0f4a34479d86","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field f0caf016-9e6b-4bca-9627-d03d3bf62b7b --><h3>What dose of duloxetine should I prescribe?</h3><!-- end field f0caf016-9e6b-4bca-9627-d03d3bf62b7b -->","summary":"","htmlStringContent":"<!-- begin item 5074c106-57f2-4063-a691-4c3a57bc07ca --><!-- begin field 0b373e55-d699-4ef9-bbe2-2162653046e8 --><ul><li>For the management of symptoms of stress urinary incontinence:<ul><li>The recommended dose of duloxetine is 40 mg taken twice a day.</li><li>Re-assess after 2–4 weeks of treatment to evaluate the benefit and tolerability of the treatment.</li></ul></li><li>If adverse effects are likely to be a problem, consider starting treatment at a dosage of 20 mg twice a day for 2 weeks before increasing to the recommended dosage of 40 mg twice a day.</li><li>For information on treatment reduction and discontinuation, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/prescribing-information/duloxetine/#drug-withdrawal-or-dose-reduction\">Drug withdrawal or dose reduction</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 0b373e55-d699-4ef9-bbe2-2162653046e8 --><!-- end item 5074c106-57f2-4063-a691-4c3a57bc07ca -->","subChapters":[]},{"id":"849df39e-dbe4-579e-aeb9-a959d0387dc6","slug":"drug-withdrawal-or-dose-reduction","fullItemName":"Drug withdrawal or dose reduction","depth":3,"htmlHeader":"<!-- begin field 10b923e5-f380-4eda-b30c-cf6bfe8f50fc --><h3>What issues should I consider when withdrawing or reducing the dose of duloxetine?</h3><!-- end field 10b923e5-f380-4eda-b30c-cf6bfe8f50fc -->","summary":"","htmlStringContent":"<!-- begin item 0b30ca79-db67-402b-8cad-4a5d94d7ced8 --><!-- begin field aa94c4a6-c7ca-4bb4-a1d1-d6124d1175b4 --><ul><li>Advise the person not to stop treatment abruptly.</li><li>If duloxetine treatment is to be discontinued, reduce the dose gradually over at least 1 to 2 weeks to reduce the risk of withdrawal reactions.</li><li>If intolerable withdrawal reactions occur after a dose reduction or on stopping treatment, resume the previously prescribed dose and continue decreasing the dose more gradually.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019f</a>]</p><!-- end field aa94c4a6-c7ca-4bb4-a1d1-d6124d1175b4 --><!-- end item 0b30ca79-db67-402b-8cad-4a5d94d7ced8 -->","subChapters":[]},{"id":"fc057ee5-eaab-5cd8-bdb8-126f529bbc2e","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 33849ae8-90e5-4789-b216-0fc80ccdbb4c --><h3>What are the key drug interactions with duloxetine?</h3><!-- end field 33849ae8-90e5-4789-b216-0fc80ccdbb4c -->","summary":"","htmlStringContent":"<!-- begin item 820519e3-3ea0-44ac-9552-61f90a517dd8 --><!-- begin field aec22a3a-430e-4ccc-a989-2c1623e87593 --><ul><li><strong>Drug interactions with duloxetine include:</strong><ul><li><strong>Aspirin, NSAIDs, and antiplatelets </strong>— increased risk of bleeding if taken concomitantly with duloxetine.</li><li><strong>Drugs metabolised by CYP2D6 </strong>(for example risperidone, tricyclic antidepressants, flecainide, metoprolol) — duloxetine is a moderate inhibitor of CYP2D6. </li><li><strong>Ciprofloxacin</strong> — may increase levels of duloxetine. Concurrent use is contraindicated.</li><li><strong>Anticoagulants</strong> — duloxetine possibly enhances the anticoagulant effect of warfarin. Use with caution or avoid.</li><li><strong>Other sedative drugs (for example antipsychotics, benzodiazepines, sedative antihistamines)</strong> — use caution if considering concurrent use of duloxetine and other centrally acting drugs.</li></ul></li><li><strong>Serotonin syndrome may occur with duloxetine, particularly if the person is also taking other serotonergic agents, drugs that impair the metabolism of serotonin, or antipsychotic drugs or dopamine antagonists that may affect serotonergic neurotransmitter systems. </strong>These include:<ul><li>Monoamine oxidase inhibitors (MAOIs) — concurrent use is contraindicated. </li><li>SSRIs. </li><li>SNRIs.</li><li>Tricyclic antidepressants.</li><li>Triptans. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field aec22a3a-430e-4ccc-a989-2c1623e87593 --><!-- end item 820519e3-3ea0-44ac-9552-61f90a517dd8 -->","subChapters":[]},{"id":"413439c6-e507-5c3e-99c0-39f7c880afc4","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 770206a9-62c1-48d5-abcd-b07526156002 --><h3>What adverse effects of duloxetine should I be aware of?</h3><!-- end field 770206a9-62c1-48d5-abcd-b07526156002 -->","summary":"","htmlStringContent":"<!-- begin item aea3d7cc-d59b-41d8-809d-e67defb4e9bd --><!-- begin field f5edd002-03fd-4f7e-9c69-4201231cacbb --><p><strong>The most common adverse effects seen in clinical trials of duloxetine for stress urinary incontinence and other lower urinary tract disorders were nausea, dry mouth, fatigue, and constipation. </strong>Other adverse effects include:</p><ul><li><strong>Cardiac</strong> — palpitation; tachycardia, supraventricular arrhythmia (rare).</li><li><strong>Gastrointestinal</strong> (GI) —  vomiting, diarrhoea, dyspepsia, abdominal pain (common); gastrointestinal haemorrhage, gastroenteritis, dysphagia, flatulence (uncommon).<ul><li><strong>Rarely</strong>: microscopic colitis.</li></ul></li><li><strong>Nervous system </strong>— headache, somnolence; dizziness, lethargy, tremor, paraesthesia (common); nervousness, akathisia, myoclonus, dyskinesia (uncommon/rare).<ul><li><strong>Rarely</strong>: serotonin syndrome, convulsions, psychomotor restlessness, extrapyramidal symptoms.</li></ul></li><li><strong>Psychiatric </strong>— insomnia, anxiety, agitation, sleep disorder (common); abnormal dreams, disorientation (uncommon).<ul><li><strong>Rarely</strong>: suicidal thoughts/behaviour, mania, hallucinations, aggression, anger.</li></ul></li><li><strong>Skin and subcutaneous tissue </strong>— increased sweating (common); rash, urticaria, dermatitis, (uncommon).<ul><li><strong>Rarely</strong>: Stevens-Johnson syndrome, photosensitivity, angioneurotic oedema.</li></ul></li><li>Also:<ul><li>Blood pressure increases, flushing.</li><li>Blurred vision.</li><li>Cholesterol level increases.</li><li>Decreased appetite.</li><li>Sexual dysfunction.</li><li>Hepatitis.</li><li>Hyponatraemia, syndrome of inappropriate antidiuretic hormone secretion (SIADH). </li><li>Tinnitus.</li><li>Urinary problems.</li><li>Yawning.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field f5edd002-03fd-4f7e-9c69-4201231cacbb --><!-- end item aea3d7cc-d59b-41d8-809d-e67defb4e9bd -->","subChapters":[]},{"id":"10e289fb-e7af-5860-83d2-827100e903b0","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 382a8eff-bc56-4468-8d93-cd09fa2083f5 --><h3>What monitoring is required for duloxetine?</h3><!-- end field 382a8eff-bc56-4468-8d93-cd09fa2083f5 -->","summary":"","htmlStringContent":"<!-- begin item 64278839-1f45-4d04-8361-c2f005bc7c35 --><!-- begin field 66056903-ea6b-4404-b714-46f1ab729df7 --><ul><li><strong>In people with hypertension or other cardiac disease, </strong>monitor blood pressure, especially during the first month.<ul><li>If a sustained increase in BP occurs, consider either a dose reduction or a gradual discontinuation of duloxetine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019f</a>]</p><!-- end field 66056903-ea6b-4404-b714-46f1ab729df7 --><!-- end item 64278839-1f45-4d04-8361-c2f005bc7c35 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}